Latest research on Rosuvastatin

Rosuvastatin is an antilipemic agent that competitively inhibits hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase. HMG-CoA reducuase catalyzes the conversion of HMG-CoA to mevalonic acid, the rate-limiting step in cholesterol biosynthesis. Rosuvastatin belongs to a class of medications called statins and is used to reduce plasma cholesterol levels and prevent cardiovascular disease.

Rosuvastatin dosage

Several factors can influence residual risk; this is associated with patients at very high risk with concomitant diseases and polypharmacy, and the problem of significant underuse of high doses of statins – in many European countries as well as in the United States Atorvastatin 80 mg or Rosuvastatin 40 mg is used in <5 % of dyslipidaemic patients [20–22]. [source, 2016]
The dose of Rosuvastatin was chosen to elicit pleiotropic effects in the absence of lipid lowering as previously reported [23,24]. [source, 2016]
Amongst these patients, 3/5 were under a high dose of statins (i.e. Rosuvastatin 20 mg once daily). [source, 2016]
Hyperlipidemic patients administered with Rosuvastatin 10 or 20 mg/day for 3 months, for example, show a dose-dependent increase in urinary low-molecular protein α-1 microglobulin 176. [source, 2015]
Renal failure has been rarely reported with high doses (80 mg/day) of Rosuvastatin. [source, 2015]
Zeybek et al. showed that in PTC and normal thyroid cell lines treatment with Rosuvastatin, the statin inhibited the cell proliferation and induced cell death in a dose-dependent manner. [source, 2015]
This study evaluated these hypotheses by investigating the in vivo time-dependent and dose-dependent effects of daily Atorvastatin or Rosuvastatin oral therapy initiated either 1 day or 3 days after venous thrombosis (VT) formation, in established, already formed stasis or nonstasis chemical-induced murine VT. [source, 2015]
Rosuvastatin (ROS, MGH Pharmacy) was administered by daily gavage in 0.1mL of PBS at a concentration of 0.28 mg/kg or 0.84 mg/kg (ROS Low and ROS, respectively, at ~25% matched lower doses compared to ATV, due to ROS’ higher potency). [source, 2015]
Low-dose Atorvastatin (ATV Low, 0.38 mg/kg) and low-dose Rosuvastatin (ROS Low, 0.28 mg/kg) did not significantly reduce VT mass compared to PBS at day 4 (Fig. 1A). [source, 2015]
TCDD-inducible transcriptional activity of AhR was dose-dependently inhibited by 3R5S- Rosuvastatin and 3R5S-fluvastatin. [source, 2015]